Horizon adds AZ’s Galbraith to board

Horizon Discovery has appointed two new board members, AstraZeneca's head of oncology R&D Susan Galbraith and Susan Searle, ex-CEO of Imperial Innovations Group.

Galbraith is senior VP and head of oncology innovative medicines at AZ and knows Horizon well thanks to a collaboration between the two companies on personalised cancer treatments.

Targeted therapies were a point of note in a recent PMLiVE interview with Galbraith, where she also discussed the rise of immunotherapies and the potential of drug combinations.

Her past experience includes a period as VP of oncology and clinical biomarkers at Bristol-Myers Squibb.

Searle has a more entrepreneurial background, co-founding the technology venture investment business Imperial Innovations Group, where she spent 11 years as its CEO - during which time the company invested £120m in life science companies.

She also sits on the advisory board for the Technology Strategy Board's Emerging Technologies group.

Darrin Disley, CEO of Horizon, said of Galbraith and Searle: “Both have established highly successful careers in their chosen fields and also have proven leadership and advisory success.

“We believe each will be an invaluable asset to Horizon, and look forward to benefitting from their counsel.”